Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Meeting Results* for: March 4, 2009

Drug Name Review Type Committee Recommendation Prior Approval Status � Final Determination
Sancuso New Drug Initial Review Remove Prior Approval Requirement Prior Approval Requirement Removed
Moxatag New Drug Initial Review Require Prior Approval Prior Approval Required
Astepro New Drug Initial Review Remove Prior Approval Requirement Prior Approval Requirement Removed
Trilipix New Drug Initial Review Require Prior Approval Prior Approval Required
Stavzor New Drug Initial Review Require Prior Approval Prior Approval Required
Janumet New Drug Initial Review Remove Prior Approval Requirement Prior Approval Required
Banzel New Drug Initial Review Require Prior Approval Prior Approval Required
Tekturna HCT New Drug Initial Review Require Prior Approval Prior Approval Required
Letairis New Drug Appeal Remove Prior Approval Requirement Prior Approval Requirement Removed
Megace ES New Drug Appeal Require Prior Approval Prior Approval Required
Bystolic New Drug Appeal Remove Prior Approval Requirement Prior Approval Required
Pristiq New Drug Appeal Require Prior Approval Prior Approval Required
Keppra XR New Drug Appeal Require Prior Approval Prior Approval Required
Exforge New Drug Appeal Require Prior Approval Prior Approval Required
Tekturna New Drug Appeal Require Prior Approval Prior Approval Required